Literature DB >> 7773542

A new class of furoxan derivatives as NO donors: mechanism of action and biological activity.

R Ferioli1, G C Folco, C Ferretti, A M Gasco, C Medana, R Fruttero, M Civelli, A Gasco.   

Abstract

1. The mechanism of action and biological activity of a series of R-substituted and di-R-substituted phenylfuroxans is reported. 2. Maximal potency as vasodilators on rabbit aortic rings, precontracted with noradrenaline (1 microM), was shown by phenyl-cyano isomers and by the 3,4-dicyanofuroxan, characterized by a potency ratio 3-10 fold higher than glyceryl trinitrate (GTN). This effect was reduced upon coincubation with methylene blue or oxyhaemoglobin (10 microM). 3. The furoxan derivatives showing maximal potency as vasodilators were also able to inhibit collagen-induced platelet aggregation, with IC50 values in the sub-micromolar range. 4. The furoxan derivatives were able to stimulate partially purified, rat lung soluble guanylate cyclase; among the most active compounds, the 3-R-substituted isomers displayed a higher level of stimulatory effect than the 4-R analogues. 5. Solutions (0.1 mM) of all the tested furoxans, prepared using 50 mM phosphate buffer, pH 7.4, (diluting 10 mM DMSO stock solutions) did not release nitric oxide (NO) spontaneously; however in presence of 5 mM L-cysteine, a significant NO-releasing capacity was observed, which correlated significantly with their stimulation of the guanylate cyclase activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773542      PMCID: PMC1510189          DOI: 10.1111/j.1476-5381.1995.tb13277.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Aggregation of blood platelets by adenosine diphosphate and its reversal.

Authors:  G V BORN
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

2.  Nature of endothelium-derived relaxing factor: are there two relaxing mediators?

Authors:  G M Rubanyi; P M Vanhoutte
Journal:  Circ Res       Date:  1987-11       Impact factor: 17.367

3.  Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.

Authors:  L J Ignarro; G M Buga; K S Wood; R E Byrns; G Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Mechanism of tolerance development to organic nitrates.

Authors:  P Needleman; E M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

5.  Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.

Authors:  L J Ignarro; H Lippton; J C Edwards; W H Baricos; A L Hyman; P J Kadowitz; C A Gruetter
Journal:  J Pharmacol Exp Ther       Date:  1981-09       Impact factor: 4.030

6.  Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

7.  Flow-dependent, endothelium-mediated dilation of epicardial coronary arteries in conscious dogs: effects of cyclooxygenase inhibition.

Authors:  J Holtz; U Förstermann; U Pohl; M Giesler; E Bassenge
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

8.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

9.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

10.  L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells.

Authors:  J B Hibbs; Z Vavrin; R R Taintor
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

View more
  11 in total

1.  Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents.

Authors:  Isaac T Schiefer; Lawren VandeVrede; Mauro Fa'; Ottavio Arancio; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2012-03-30       Impact factor: 7.446

2.  In Vitro Metabolic Stability and in Vivo Biodistribution of 3-Methyl-4-furoxancarbaldehyde Using PET Imaging in Rats.

Authors:  Adam B Pippin; Zaira Hidayah Mohd Arshad; Ronald J Voll; Jonathon A Nye; Sussan Ghassabian; Craig M Williams; Alessandra Mancini; Dennis C Liotta; Maree T Smith; Mark M Goodman
Journal:  ACS Med Chem Lett       Date:  2016-03-30       Impact factor: 4.345

3.  NO donor and biological properties of different benzofuroxans.

Authors:  C Medana; A Di Stilo; S Visentin; R Fruttero; A Gasco; D Ghigo; A Bosia
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

4.  Studies on agents with mixed NO-dependent vasodilating and beta-blocking activities.

Authors:  D Boschi; A Di Stilo; C Cena; M Lolli; R Fruttero; A Gasco
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

5.  Vasorelaxant and antiplatelet activity of 4,7-dimethyl-1,2, 5-oxadiazolo[3,4-d]pyridazine 1,5,6-trioxide: role of soluble guanylate cyclase, nitric oxide and thiols.

Authors:  A Y Kots; M A Grafov; Y V Khropov; V L Betin; N N Belushkina; O G Busygina; M Y Yazykova; I V Ovchinnikov; A S Kulikov; N N Makhova; N A Medvedeva; T V Bulargina; I S Severina
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 6.  Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.

Authors:  A M Mfuh; O V Larionov
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

7.  Nitric oxide reduces the palmitoylation of rat myelin proteolipid protein by an indirect mechanism.

Authors:  O A Bizzozero; H Bixler; J Parkhani; A Pastuszyn
Journal:  Neurochem Res       Date:  2001-10       Impact factor: 3.996

8.  The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative CHF 2363.

Authors:  M Civelli; M Giossi; P Caruso; R Razzetti; M Bergamaschi; S Bongrani; A Gasco
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

9.  Nucleophilic dearomatization of 4-aza-6-nitrobenzofuroxan by CH acids in the synthesis of pharmacology-oriented compounds.

Authors:  Alexey M Starosotnikov; Dmitry V Shkaev; Maxim A Bastrakov; Ivan V Fedyanin; Svyatoslav A Shevelev; Igor L Dalinger
Journal:  Beilstein J Org Chem       Date:  2017-12-21       Impact factor: 2.883

Review 10.  Chalcone Derivatives: Promising Starting Points for Drug Design.

Authors:  Marcelo N Gomes; Eugene N Muratov; Maristela Pereira; Josana C Peixoto; Lucimar P Rosseto; Pedro V L Cravo; Carolina H Andrade; Bruno J Neves
Journal:  Molecules       Date:  2017-07-25       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.